1800-272-662
Shopping Cart 0
countryflagAU
Login

Nyrada Inc

Healthcare AU NYR

0.515AUD
-0.035(6.36%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.490.55
LowHigh

52 Week Range

0.091.44
LowHigh

Fundamentals

  • Previous Close 0.55
  • Market Cap124.92M
  • Volume983980
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.68133M
  • Revenue TTM2.38M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM -1.84674M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -4.84567M -4.60137M -7.78169M -3.95966M -3.53925M
Minority interest - - - - -
Net income -4.84567M -1.38623M -7.78169M -3.96105M -5.88088M
Selling general administrative 1.44M 1.06M 2.28M 2.67M 2.94M
Selling and marketing expenses 1.40M 1.49M - - -
Gross profit -1.97948M -0.81392M - - -
Reconciled depreciation 0.00378M 0.00518M 0.00653M 0.00473M 0.00181M
Ebit -5.00774M -4.60137M -9.36041M -3.95827M -3.53365M
Ebitda -5.00396M -4.59620M -9.35388M -3.95354M -3.53184M
Depreciation and amortization 0.00378M 0.00516M 0.00653M 0.00473M 0.00181M
Non operating income net other - - - - -
Operating income -9.20109M -4.56033M -9.36041M -3.95827M -3.53365M
Other operating expenses 11.60M 6.60M 9.36M 5.07M 5.87M
Interest expense - - - 0.00139M 0.00560M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.16M 0.16M 0.15M 0.01M 0.00561M
Net interest income 0.16M 0.16M 0.15M 0.01M -0.00162M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.40082M -3.21514M -0.14882M 0.00139M 2.34M
Total revenue 2.40M 3.24M 1.58M 1.11M 2.34M
Total operating expenses 7.22M 4.56M 9.36M 5.07M 5.87M
Cost of revenue 4.38M 2.03M - - -
Total other income expense net 4.36M -0.04103M 1.43M -0.00139M -0.00560M
Discontinued operations - - - - -
Net income from continuing ops -4.84567M -1.39131M -7.78169M -3.95966M -3.53925M
Net income applicable to common shares -4.84567M -1.39131M -7.78169M -3.95966M -3.53925M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 5.30M 5.91M 5.16M 12.01M 15.16M
Intangible assets 0.03M - 0.03M 0.04M 0.04M
Earning assets - - - - -
Other current assets - 0.08M - 0.08M 0.00169M
Total liab 1.72M 0.86M 0.91M 0.52M 0.67M
Total stockholder equity 3.58M 5.05M 4.26M 11.50M 14.49M
Deferred long term liab - - - - -
Other current liab - 0.72M 0.38M 0.41M 0.08M
Common stock - 26.84M 25.32M 25.32M 25.32M
Capital stock 29.77M - 25.32M 25.32M 25.32M
Retained earnings -29.57654M -27.19013M -27.21673M -19.51528M -15.55562M
Other liab - - 0.02M 0.04M -
Good will - - - - -
Other assets - - - - -
Cash 2.93M 4.77M 3.71M 10.82M 13.75M
Cash and equivalents - - - 10.82M 13.75M
Total current liabilities 1.72M 0.84M 0.88M 0.47M 0.67M
Current deferred revenue - - - - -
Net debt - -4.76937M -3.70876M -10.81604M -13.75074M
Short term debt - - - 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - 6.15M 5.69M 4.73M
Property plant equipment - - 0.00448M 0.00873M 0.00844M
Total current assets 5.27M 5.87M 5.13M 11.97M 15.11M
Long term investments - - - - -
Net tangible assets - - 4.22M 11.46M 14.45M
Short term investments - - - - -
Net receivables 2.16M 1.02M 1.42M 1.07M 1.36M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.91M 0.12M 0.51M 0.07M 0.59M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 5.40M 6.15M 5.69M 4.73M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.03M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.03M 0.03M 0.04M 0.04M 0.05M
Capital lease obligations - - - - -
Long term debt total - - - 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.00000M 0.00000M - -0.00476M -0.00500M
Change to liabilities - - 0.25M -0.19798M -0.09862M
Total cashflows from investing activities 0.00000M 0.00000M 0.00000M -0.00476M -0.00500M
Net borrowings - - - - -0.34232M
Total cash from financing activities 3.19M 1.83M 0.00000M -0.26896M 11.34M
Change to operating activities - - 0.05M 0.06M 0.03M
Net income -4.84567M -1.38623M -7.78169M -3.96105M -3.53925M
Change in cash -1.83877M 1.06M -7.10728M -2.93470M 8.60M
Begin period cash flow 4.77M 3.71M 10.82M 13.75M 5.15M
End period cash flow 2.93M 4.77M 3.71M 10.82M 13.75M
Total cash from operating activities -5.05195M -0.76629M -7.19939M -3.95631M -2.77285M
Issuance of capital stock 3.45M 1.97M - - 11.87M
Depreciation 0.00378M 0.00516M 0.00653M 0.00473M 0.00181M
Other cashflows from investing activities 0.00000M 0.00000M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -1.23552M 0.31M -0.26414M 0.21M -0.28198M
Sale purchase of stock -0.25394M -0.13807M - -0.22444M -0.23429M
Other cashflows from financing activities 3.19M 0.00667M 0.00000M -0.04452M 0.04M
Change to netincome - - 0.54M 0.97M 1.11M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00476M 0.00500M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.18937M 0.26M 1.32M 1.37M 2.11M
Stock based compensation 0.18M - - - -
Other non cash items 0.80M 0.36M - 3.96M 3.54M
Free cash flow -5.05195M -0.76629M -7.19939M -3.96107M -2.77785M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
NYR
Nyrada Inc		 -0.035 6.36% 0.52 - - 52.51 13.69 -2.1744
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

Nyrada Inc

Sydney Place, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. James Bonnar Chief Exec. Officer NA
Mr. Cameron Jones C.A. Chief Financial Officer NA
Mr. Benjamin Evison Ph.D. Chief Scientific Officer NA
Ms. Laura Vize Investor Relations Mang. NA
Mr. Mark Waring B.Sc., P.M.P. Sr. VP of US Operations NA
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. Company Sec. 1970
Mr. James Bonnar Chief Executive Officer NA
Mr. Dimitri Burshtein Investor Relations Manager NA
Mr. Mark Waring B.Sc., P.M.P. Senior Vice President of US Operations NA
Mr. David James Franks BEc, C.A., F Fin, J.P. Company Secretary 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.